Workflow
ONCOTELIC CLINICAL PRESENTATIONS AT SITC 2024
SITE Centers SITE Centers (US:SITC) GlobeNewswire News Roomยท2024-11-06 15:47

Core Insights - Oncotelic Therapeutics, Inc. presented its research at SITC 2024, focusing on the TGFB2 therapeutics pipeline [1] - Dr. Cynthia Lee, VP of R&D, has been instrumental in leading R&D programs and the establishment of a GMP facility in San Diego [1] Research Presentations - Abstract Number 198 discusses the interaction of TGFB2 mRNA levels with Interferon-alpha receptor activation and its impact on overall survival in pancreatic ductal adenocarcinoma (PDAC) [1] - Abstract Number 218 evaluates the prognostic impact of TGFB2 mRNA levels in low-grade gliomas, in conjunction with Interferon-gamma receptor activation [1] - Abstract Number 1444 presents a meta-analysis comparing serious adverse events and survival outcomes in PDAC patients treated with mFOLFIRINOX or FOLFIRINOX [1] Company Overview - Oncotelic has a rare pediatric designation for Diffuse Intrinsic Pontine Glioma (DIPG) through its joint venture, GMP Biotechnology Limited, and is involved in treatments for melanoma and Acute Myeloid Leukemia [2] - The company acquired PointR Data Inc. in November 2019 to enhance its AI-driven biotechnology capabilities [2] - Oncotelic is developing AL-101 for various conditions, including Parkinson's Disease and sexual disorders, addressing a significant patient population [2] - The first-in-class TGFB2 therapeutic for pancreatic cancer and glioblastoma is being developed through its joint venture, Sapu Bio [2]